HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance77% confidence

FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

Source: FDA

Why This Matters

Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Dr. Reddy's Labs; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Application ANDA075351. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

Supporting Context

Therapeutic area
Diabetes · DPP-4 Inhibitor
Sub-indication
General

Related signal: FDA Accepts ANDA for Sitagliptin Phosphate by Dr. Reddy's Labs

Source

View source document

Related Signal

Open signal — FDA Accepts ANDA for Sitagliptin Phosphate by Dr. Reddy's Labs
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.